Monthly Sublocade May Be A Treatment Option For Opioid Use Disorder During & After Pregnancy  

The use of monthly Sublocade® during pregnancy demonstrated no increased risk and is consistent with the established buprenorphine safety profile, according to a study. Sublocade is a branded medication that combines buprenorphine and naloxone in an extended-release formulation to treat women with opioid use disorder (OUD). The researchers stated that the findings support the use of buprenorphine extended-release medication as part of evidence-based treatment for OUD during the perinatal period.   

The researchers analyzed electronic medical record (EMR) data from a perinatal substance use disorder program in North Carolina, and also reviewed Indivior's Global Safety Database, containing . . .